Combination product for use in tumor vaccination
The present invention relates to a combination product for use in eliciting an immune response against a tumor in a subject, said product comprising: —an immunogenic composition comprising a non-human antigenic polypeptide as an immunogen, or comprising a nucleic acid encoding said immunogen, and optionally one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents; and—said non-human antigenic polypeptide, or a nucleic acid encoding said polypeptide; wherein said polypeptide or said nucleic acid is prepared for intratumoral delivery. The invention also provides fusion proteins and protein-protein conjugates that can be used in the medical methods described herein.
1. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell and a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen,
wherein the time between the vaccination step and the tumor-marking step is within 21 days
thereby generating an immune response against the solid tumor in the subject.
2. The method of claim 1 , further comprising one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
3. The method of claim 1 , wherein the tumor marking-step comprises administering the second composition into the tumor.
4. The method of claim 1 , wherein the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, intradermal, subcutaneous, intravenous, intraarterial, intraperitoneal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
5. The method of claim 1 , wherein the tumor-marking step is performed subsequent to the vaccination step.
6. The method of claim 1 , wherein the solid tumor is selected from the group consisting of glioblastoma and ovarian cancer.
7. The method of claim 1 , wherein the second composition is further comprises a tumor targeting component selected from the group consisting of a tumor-specific virus, an oncolytic virus, and a tumor-specific nanoparticle.
8. The method of claim 1 , wherein
the CD34-positive, CD1a-positive, and CD83-positive cell is differentiated from DCOne.
9. The method of claim 1 , wherein the first and second compositions each comprise one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
10. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell and the non-tumor antigen or a nucleic acid encoding the non-tumor antigen,
wherein the time between the vaccination step and the tumor-marking step is within 21 days,
thereby generating an immune response against the solid tumor in the subject.
11. The method of claim 10 , further comprising one or more booster steps each comprising administering a booster composition to the subject, wherein the booster composition comprises the non-tumor antigen or a nucleic acid encoding the non-tumor antigen.
12. The method of claim 10 , wherein the tumor marking-step comprises administering the second composition into the tumor.
13. The method of claim 10 , wherein the vaccination step comprises administering the first composition via a route selected from the group consisting of intramuscular, intradermal, subcutaneous, intravenous, intraarterial, intraperitoneal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue.
14. The method of claim 10 , wherein the tumor-marking step is performed subsequent to the vaccination step.
15. The method of claim 10 , wherein the solid tumor is selected from the group consisting of glioblastoma and ovarian cancer.
16. The method of claim 10 , wherein the second composition further comprises a tumor targeting component selected from the group consisting of a tumor-specific virus, an oncolytic virus, and a tumor-specific nanoparticle.
17. The method of claim 10 , wherein the CD34-positive, CD1a-positive, and CD83-positive cell is differentiated from DCOne.
18. The method of claim 10 , wherein the first and second compositions each comprise one or more pharmaceutically-acceptable carriers, adjuvants, excipients and/or diluents.
19. A method for generating an immune response against a solid tumor in a subject comprising:
a vaccination step comprising administering a first composition to the subject at a site distal to a solid tumor site, wherein the first composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell and a non-tumor antigen or a nucleic acid encoding the non-tumor antigen; and
a tumor-marking step comprising administering a second composition to the subject at the solid tumor site, wherein the second composition comprises a CD34-positive, CD1a-positive, and CD83-positive cell and the non-tumor antigen or a nucleic acid encoding the non-tumor antigen,
wherein the time between the vaccination step and the tumor-marking step is within 21 days,
thereby generating an immune response against the solid tumor in the subject.
20. The method of claim 19 , wherein the CD34-positive, CD1a-positive, and CD83-positive cell is differentiated from DCOne.